177Lu-LNC1003
/ Dongcheng Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 24, 2024
The Safety and Dosimetry Study of 177Lu-LNC1003 Injection
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. | Initiation date: May 2024 ➔ May 2025
Metastases • Trial initiation date • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
July 10, 2024
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
(clinicaltrials.gov)
- P=N/A | N=9 | Recruiting | Sponsor: Peking Union Medical College Hospital | Trial completion date: Nov 2023 ➔ Nov 2025 | Trial primary completion date: Jun 2023 ➔ Jun 2025
Metastases • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1
February 01, 2024
The Safety and Dosimetry Study of 177Lu-LNC1003 Injection
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD.
New P1 trial • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
November 14, 2022
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
(clinicaltrials.gov)
- P=N/A | N=9 | Recruiting | Sponsor: Peking Union Medical College Hospital
New trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1
1 to 4
Of
4
Go to page
1